	US 11,779,536 B2
	Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
Charles D. Blizzard, Nashua, NH (US); Rami El-Hayek, Norwood, MA (US); Michael Goldstein, Cambridge, MA (US); Peter Jarrett, Burlington, MA (US); and Andrew Vanslette, Bolton, MA (US)
Assigned to Ocular Therapeutix, Inc., Bedford, MA (US)
Filed by Ocular Therapeutix, Inc., Bedford, MA (US)
Filed on Feb. 25, 2022, as Appl. No. 17/681,238.
Application 17/681,238 is a continuation of application No. 17/483,220, filed on Sep. 23, 2021, granted, now 11,331,267.
Claims priority of provisional application 63/124,204, filed on Dec. 11, 2020.
Claims priority of provisional application 63/082,505, filed on Sep. 24, 2020.
Prior Publication US 2022/0202706 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 38/13 (2006.01); A61K 47/10 (2017.01); A61K 47/22 (2006.01); A61P 27/02 (2006.01)

CPC A61K 9/0051 (2013.01) [A61K 38/13 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61P 27/02 (2018.01)]

20 Claims

1. An ocular composition comprising a sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, wherein the cyclosporine is in the form of particles having d50 value of less than about 50 μm as measured by laser diffraction and wherein the cyclosporine particles are dispersed within the hydrogel, wherein the hydrogel comprises a polymer network comprising crosslinked polymer units that are identical or different which are polyethylene glycol units having two to ten arms, wherein the arms of the polyethylene glycol units are connected to a core molecule of pentaerythritol, the polymer network is formed by reacting an electrophilic group-containing multi-arm polymer precursor with a nucleophilic group-containing cross-linking agent, the electrophilic group is an N-hydroxysuccinimidyl (NHS) ester group, the nucleophilic group-containing crosslinking agent contains an amine group.